Literature DB >> 29034548

Electroacupuncture alleviates chemotherapy-induced pain through inhibiting phosphorylation of spinal CaMKII in rats.

Y Zhang1, A Li2, J Xin2, K Ren3, B M Berman2, L Lao2, R-X Zhang2.   

Abstract

BACKGROUND: Current medical treatments for chemotherapy-induced pain (CIP) are either ineffective or have adverse side effects. Acupuncture may alleviate CIP, but its effectiveness against this condition has not been studied. Paclitaxel causes neuropathic pain in cancer patients.
METHODS: We evaluated the effects of electroacupuncture (EA) on paclitaxel-induced CIP in a rat model. Paclitaxel (2 mg/kg) or vehicle was injected (i.p.) on alternate days of 0-6. The resulting pain was treated with 10 Hz/2 mA/0.4 ms pulse EA for 30 min at the equivalent of human acupoint GB30 (Huantiao) once every other day between days 14 and 26. For sham control, EA needles were inserted into GB30 without stimulation. Von Frey filaments with bending forces of 2-8 g and 15 g were used to assess mechanical allodynia and hyperalgesia, respectively, on day 13 and once every other day between 14-26 days and then for 2-3 weeks after EA treatment.
RESULTS: Compared to sham control, EA significantly alleviated paclitaxel-induced mechanical allodynia and hyperalgesia, as shown by less frequent withdrawal responses to the filaments. The alleviation of allodynia/hyperalgesia lasted up to 3 weeks after the EA treatment. EA significantly inhibited phosphorylation of Ca2+ /calmodulin-dependent protein kinase II (CaMKII) in the spinal cord. KN-93, a selective inhibitor of p-CaMKII, inhibited mechanical allodynia/hyperalgesia and p-CaMKII. 5-HT1A receptor antagonist blocked EA inhibition of allodynia/hyperalgesia and p-CaMKII.
CONCLUSIONS: Electroacupuncture activates 5-HT 1A receptors in the spinal cord and inhibits p-CaMKII to alleviate both allodynia and hyperalgesia. The data support acupuncture/EA as a complementary therapy for CIP. SIGNIFICANCE: Electroacupuncture (EA) activates spinal 5-HT1A receptors to inhibit p-CaMKII to alleviate paclitaxel-induced pain. Acupuncture/EA may be used as a complementary therapy for CIP.
© 2017 European Pain Federation - EFIC®.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29034548      PMCID: PMC5854511          DOI: 10.1002/ejp.1132

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  59 in total

1.  The central serotonergic system mediates the analgesic effect of electroacupuncture on ZUSANLI (ST36) acupoints.

Authors:  Fang-Chia Chang; Huei-Yann Tsai; Ming-Chien Yu; Pei-Lu Yi; Jaung-Geng Lin
Journal:  J Biomed Sci       Date:  2004 Mar-Apr       Impact factor: 8.410

Review 2.  Chemotherapy-induced peripheral neurotoxicity.

Authors:  Guido Cavaletti; Paola Marmiroli
Journal:  Expert Opin Drug Saf       Date:  2004-11       Impact factor: 4.250

3.  KN-93 (2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), a calcium/calmodulin-dependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated potassium channels.

Authors:  Saman Rezazadeh; Thomas W Claydon; David Fedida
Journal:  J Pharmacol Exp Ther       Date:  2005-12-20       Impact factor: 4.030

Review 4.  Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.

Authors:  Sherry Wolf; Debra Barton; Lisa Kottschade; Axel Grothey; Charles Loprinzi
Journal:  Eur J Cancer       Date:  2008-06-18       Impact factor: 9.162

5.  Analgesic effect of electroacupuncture on inflammatory pain in the rat model of collagen-induced arthritis: mediation by cholinergic and serotonergic receptors.

Authors:  Yong Hyeon Baek; Do Young Choi; Hyung In Yang; Dong Suk Park
Journal:  Brain Res       Date:  2005-09-28       Impact factor: 3.252

6.  Antiallodynic effect of tianeptine via modulation of the 5-HT7 receptor of GABAergic interneurons in the spinal cord of neuropathic rats.

Authors:  Hai Lin; Bong Ha Heo; Woong Mo Kim; Yong Chul Kim; Myung Ha Yoon
Journal:  Neurosci Lett       Date:  2015-05-14       Impact factor: 3.046

7.  Quantitative assessment of tactile allodynia in the rat paw.

Authors:  S R Chaplan; F W Bach; J W Pogrel; J M Chung; T L Yaksh
Journal:  J Neurosci Methods       Date:  1994-07       Impact factor: 2.390

8.  Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine.

Authors:  Harry Openshaw; Karen Beamon; Timothy W Synold; Jeff Longmate; Neal E Slatkin; James H Doroshow; Stephen Forman; Kim Margolin; Robert Morgan; Stephen Shibata; George Somlo
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

9.  The distribution of brain-stem and spinal cord nuclei associated with different frequencies of electroacupuncture analgesia.

Authors:  Lee Jang-Hern; Alvin J Beitz
Journal:  Pain       Date:  1993-01       Impact factor: 6.961

10.  Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.

Authors:  V Chaudhry; E K Rowinsky; S E Sartorius; R C Donehower; D R Cornblath
Journal:  Ann Neurol       Date:  1994-03       Impact factor: 10.422

View more
  9 in total

1.  Islet-cell autoantigen 69 mediates the antihyperalgesic effects of electroacupuncture on inflammatory pain by regulating spinal glutamate receptor subunit 2 phosphorylation through protein interacting with C-kinase 1 in mice.

Authors:  Kunyuan Han; Anqi Zhang; Yunchang Mo; Tingting Mao; Binbin Ji; Dan Li; Xiuxiu Zhuang; Meizi Qian; Shuangdong Chen; Zhen Wang; Junlu Wang
Journal:  Pain       Date:  2019-03       Impact factor: 7.926

2.  Electroacupuncture Alleviates Paclitaxel-Induced Peripheral Neuropathic Pain in Rats via Suppressing TLR4 Signaling and TRPV1 Upregulation in Sensory Neurons.

Authors:  Yuanyuan Li; Chengyu Yin; Xiaojie Li; Boyu Liu; Jie Wang; Xiaoli Zheng; Xiaomei Shao; Yi Liang; Junying Du; Jianqiao Fang; Boyi Liu
Journal:  Int J Mol Sci       Date:  2019-11-25       Impact factor: 5.923

Review 3.  The Role of Descending Pain Modulation in Chronic Primary Pain: Potential Application of Drugs Targeting Serotonergic System.

Authors:  Zhuo-Ying Tao; Pei-Xing Wang; Si-Qi Wei; Richard J Traub; Jin-Feng Li; Dong-Yuan Cao
Journal:  Neural Plast       Date:  2019-12-17       Impact factor: 3.599

4.  Neuregulin1-ErbB4 Signaling in Spinal Cord Participates in Electroacupuncture Analgesia in Inflammatory Pain.

Authors:  Chaofan Wan; Yunlong Xu; Baoyan Cen; Yucen Xia; Lin Yao; Yuanjia Zheng; Jiaying Zhao; Su He; Yongjun Chen
Journal:  Front Neurosci       Date:  2021-01-28       Impact factor: 4.677

Review 5.  Acupuncture for Paclitaxel-Induced Peripheral Neuropathy: A Review of Clinical and Basic Studies.

Authors:  Yu-Xue Zhao; Xiao-Chun Yu; Jun-Hong Gao; Ming-Jiang Yao; Bing Zhu
Journal:  J Pain Res       Date:  2021-04-15       Impact factor: 3.133

6.  Electroacupuncture Attenuates CFA-Induced Inflammatory Pain by Regulating CaMKII.

Authors:  Yixiao Gu; Shuangdong Chen; Yunchang Mo; Yingying Tu; Na Chen; Xiaoyong Zhao; Shan Li; Qimin Yu; Qinxue Dai; Junlu Wang
Journal:  Neural Plast       Date:  2020-12-31       Impact factor: 3.599

Review 7.  Clinical Efficacy and Potential Mechanisms of Acupoint Stimulation Combined With Chemotherapy in Combating Cancer: A Review and Prospects.

Authors:  Shanshan Li; Suhong Zhao; Yi Guo; Yuanzhen Yang; Jin Huang; Jiaqi Wang; Shanshan Lu; Bin Wang; Chao Chai; Zhifang Xu; Yenlie Chin
Journal:  Front Oncol       Date:  2022-04-25       Impact factor: 5.738

Review 8.  Potential mechanisms of acupuncture for neuropathic pain based on somatosensory system.

Authors:  Xin Ma; Wen Chen; Na-Na Yang; Lu Wang; Xiao-Wan Hao; Chun-Xia Tan; Hong-Ping Li; Cun-Zhi Liu
Journal:  Front Neurosci       Date:  2022-09-20       Impact factor: 5.152

9.  Electroacupuncture Treatment Attenuates Paclitaxel-Induced Neuropathic Pain in Rats via Inhibiting Spinal Glia and the TLR4/NF-κB Pathway.

Authors:  Yu-Xue Zhao; Ming-Jiang Yao; Qun Liu; Juan-Juan Xin; Jun-Hong Gao; Xiao-Chun Yu
Journal:  J Pain Res       Date:  2020-01-29       Impact factor: 3.133

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.